AGM Statement

RNS Number : 0764M

Evgen Pharma PLC

26 July 2017

 

For immediate release	26 July 2017

 

 

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

AGM Statement

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will hold its Annual General Meeting ("AGM") this afternoon in Manchester.  At the AGM, the Company's Chairman, Barry Clare, will make the following statement:

"The current year is progressing well for our Company.  SFX-01, our lead product candidate, continues to be tested in two Phase II trials in different indications, breast cancer and subarachnoid haemorrhage.

"Interest in SFX-01 and sulforaphane-based science continues apace in the academic and translational medicine communities. Earlier this month, we announced that the Manchester Cancer Research Centre will conduct preclinical research of SFX-01 in triple negative breast cancer.  Today, we can announce that the Company and the Skeletal Biology Group at the Royal Veterinary College ("RVC"), University of London, has secured grant funding to continue its collaboration and build on earlier encouraging preclinical results demonstrating the potential of SFX-01 as a treatment for osteoarthritis.  The RVC will be releasing a separate announcement later today.

"These investigator-led studies underline the broad therapeutic potential of SFX-01 and extend the Company's commercial presence in sulforaphane-based research.  Our primary focus remains on our two Phase II trials and we look forward to making further progress with these trials in the year ahead."

Dr Stephen Franklin, Evgen Pharma's CEO, will give a corporate presentation at the AGM. A copy of the presentation is available at the Company's website, www.evgen.com.

Enquiries:

Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com	c/o [phone]
Buchanan Mark Court, Sophie Cowles, Stephanie Watson		[phone]
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance) John Howes, Rob Rees (Corporate Broking)		[phone]

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

 

END

 

 

AGMEAKXSALDXEFF